Country: United States
Language: English
Source: NLM (National Library of Medicine)
QUINAPRIL HYDROCHLORIDE (UNII: 33067B3N2M) (QUINAPRILAT - UNII:34SSX5LDE5)
Bryant Ranch Prepack
ORAL
PRESCRIPTION DRUG
Quinapril tablets are contraindicated in patients who are hypersensitive to this product and in patients with a history of angioedema related to previous treatment with an ACE inhibitor.
Abbreviated New Drug Application
QUINAPRIL- QUINAPRIL TABLET, FILM COATED BRYANT RANCH PREPACK ---------- QUINAPRIL TABLETS, USP, 5 MG, 10 MG, 20 MG, AND 40 MG 1050 1051 1045 1053 RX ONLY USE IN PREGNANCY When pregnancy is detected, quinapril tablets should be discontinued as soon as possible. See , . WHEN USED IN PREGNANCY DURING THE SECOND AND THIRD TRIMESTERS, ACE INHIBITORS CAN CAUSE INJURY AND EVEN DEATH TO THE DEVELOPING FETUS.WARNINGSFETAL/NEONATAL MORBIDITY AND MORTALITY DESCRIPTION Quinapril hydrochloride is the hydrochloride salt of quinapril, the ethyl ester of a non-sulfhydryl, angiotensin-converting enzyme (ACE) inhibitor, quinaprilat. Quinapril hydrochloride is chemically described as [3 -[2[ *( *)],3 *]]-2-[2-[[1-(ethoxycarbonyl)-3- phenylpropyl]amino]-1-oxopropyl]-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid, monohydrochloride. Its structural formula is: _SRRR_ C H N O •HCl M.W. 474.98 Quinapril hydrochloride is a white to off-white amorphous powder that is freely soluble in aqueous solvents. Quinapril tablets, USP contain 5 mg, 10 mg, 20 mg, or 40 mg of quinapril for oral administration. In addition, each tablet also contains the following inactive ingredients: crospovidone, FD&C Blue No. 2 Aluminum Lake, FD&C Red No. 40 Aluminum Lake, FD&C Yellow No. 6 Aluminum Lake, gelatin, hypromellose, lactose monohydrate, magnesium carbonate, magnesium stearate, polyethylene glycol, titanium dioxide, and triacetin. CLINICAL PHARMACOLOGY MECHANISM OF ACTION Quinapril is deesterified to the principal metabolite, quinaprilat, which is an inhibitor of ACE activity in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor, angiotensin II. The effect of quinapril in hypertension appears to result primarily from the inhibition of circulating and tissue ACE activity, thereby reducing angiotensin II formation. 253025 Quinapril inhibits the elevation in blood pressure caused by intravenously administered angiotensin I, but has no effect on the pressor response to angioten Read the complete document